Zevra Therapeutics IncNASDAQ:ZVRA
- LAST PRICE4.5200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.4600/ 1
- Ask / Lots4.8500/ 19
- Open / Previous Close4.5200 / 4.5200
- Day Range
- 52 Week Range
- Volume157,431
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZVRA |
|---|---|---|
| 09:32 ET | 1915 | 4.58 |
| 09:36 ET | 100 | 4.51 |
| 09:38 ET | 100 | 4.51 |
| 09:39 ET | 200 | 4.525 |
| 09:41 ET | 100 | 4.51 |
| 09:43 ET | 350 | 4.545 |
| 09:50 ET | 100 | 4.52 |
| 09:54 ET | 200 | 4.53 |
| 09:56 ET | 100 | 4.52 |
| 09:57 ET | 610 | 4.55 |
| 09:59 ET | 125 | 4.56 |
| 10:01 ET | 100 | 4.55 |
| 10:03 ET | 200 | 4.56 |
| 10:14 ET | 400 | 4.555 |
| 10:19 ET | 120 | 4.5401 |
| 10:21 ET | 415 | 4.56 |
| 10:24 ET | 100 | 4.55 |
| 10:30 ET | 255 | 4.55 |
| 10:33 ET | 200 | 4.5507 |
| 10:35 ET | 387 | 4.554 |
| 10:37 ET | 534 | 4.565 |
| 10:44 ET | 100 | 4.57 |
| 10:48 ET | 100 | 4.57 |
| 10:51 ET | 1717 | 4.59 |
| 10:53 ET | 1155 | 4.6 |
| 10:55 ET | 100 | 4.595 |
| 11:00 ET | 165 | 4.595 |
| 11:02 ET | 100 | 4.59 |
| 11:08 ET | 293 | 4.58 |
| 11:09 ET | 100 | 4.57 |
| 11:11 ET | 300 | 4.57 |
| 11:15 ET | 100 | 4.56 |
| 11:20 ET | 107 | 4.55 |
| 11:22 ET | 200 | 4.56 |
| 11:26 ET | 200 | 4.56 |
| 11:27 ET | 600 | 4.56 |
| 11:29 ET | 600 | 4.57 |
| 11:36 ET | 380 | 4.5607 |
| 11:40 ET | 100 | 4.56 |
| 11:45 ET | 100 | 4.56 |
| 11:51 ET | 100 | 4.56 |
| 11:58 ET | 952 | 4.59 |
| 12:00 ET | 300 | 4.59 |
| 12:03 ET | 200 | 4.58 |
| 12:05 ET | 100 | 4.57 |
| 12:14 ET | 1731 | 4.58 |
| 12:18 ET | 100 | 4.58 |
| 12:21 ET | 100 | 4.58 |
| 12:25 ET | 100 | 4.57 |
| 12:27 ET | 300 | 4.571 |
| 12:30 ET | 100 | 4.57 |
| 12:32 ET | 100 | 4.57 |
| 12:34 ET | 700 | 4.58 |
| 12:36 ET | 100 | 4.58 |
| 12:38 ET | 644 | 4.59 |
| 12:39 ET | 100 | 4.59 |
| 12:41 ET | 100 | 4.59 |
| 12:50 ET | 880 | 4.58 |
| 12:57 ET | 326 | 4.59 |
| 01:10 ET | 1000 | 4.59 |
| 01:12 ET | 2205 | 4.59 |
| 01:14 ET | 458 | 4.5919 |
| 01:15 ET | 191 | 4.5904 |
| 01:17 ET | 1400 | 4.59 |
| 01:19 ET | 100 | 4.5901 |
| 01:21 ET | 300 | 4.595 |
| 01:26 ET | 1160 | 4.585 |
| 01:28 ET | 600 | 4.585 |
| 01:32 ET | 100 | 4.58 |
| 01:33 ET | 508 | 4.58 |
| 01:35 ET | 598 | 4.575 |
| 01:37 ET | 400 | 4.575 |
| 01:39 ET | 200 | 4.57 |
| 01:42 ET | 915 | 4.57 |
| 01:44 ET | 1223 | 4.585 |
| 01:46 ET | 100 | 4.585 |
| 01:50 ET | 800 | 4.58 |
| 01:53 ET | 800 | 4.59 |
| 01:57 ET | 100 | 4.59 |
| 02:00 ET | 200 | 4.59 |
| 02:06 ET | 3780 | 4.59 |
| 02:09 ET | 415 | 4.585 |
| 02:11 ET | 100 | 4.58 |
| 02:15 ET | 321 | 4.575 |
| 02:18 ET | 100 | 4.57 |
| 02:20 ET | 200 | 4.57 |
| 02:22 ET | 3661 | 4.58 |
| 02:24 ET | 299 | 4.57 |
| 02:26 ET | 200 | 4.565 |
| 02:29 ET | 300 | 4.56 |
| 02:31 ET | 438 | 4.56 |
| 02:33 ET | 1332 | 4.56 |
| 02:36 ET | 300 | 4.555 |
| 02:38 ET | 300 | 4.55 |
| 02:40 ET | 882 | 4.55 |
| 02:45 ET | 200 | 4.555 |
| 02:47 ET | 300 | 4.555 |
| 02:49 ET | 2675 | 4.55 |
| 02:51 ET | 200 | 4.55 |
| 02:54 ET | 9046 | 4.55 |
| 02:58 ET | 200 | 4.545 |
| 03:00 ET | 100 | 4.54 |
| 03:02 ET | 1604 | 4.54 |
| 03:05 ET | 100 | 4.53 |
| 03:07 ET | 822 | 4.5269 |
| 03:09 ET | 400 | 4.525 |
| 03:12 ET | 1346 | 4.53 |
| 03:16 ET | 1057 | 4.525 |
| 03:18 ET | 200 | 4.52 |
| 03:20 ET | 188 | 4.52 |
| 03:21 ET | 200 | 4.52 |
| 03:25 ET | 100 | 4.52 |
| 03:27 ET | 100 | 4.52 |
| 03:30 ET | 200 | 4.52 |
| 03:32 ET | 255 | 4.52 |
| 03:34 ET | 1350 | 4.52 |
| 03:36 ET | 600 | 4.52 |
| 03:38 ET | 100 | 4.52 |
| 03:39 ET | 100 | 4.52 |
| 03:41 ET | 300 | 4.525 |
| 03:43 ET | 1500 | 4.5215 |
| 03:45 ET | 1250 | 4.525 |
| 03:48 ET | 12862 | 4.515 |
| 03:50 ET | 2819 | 4.5 |
| 03:52 ET | 1935 | 4.49 |
| 03:54 ET | 1245 | 4.49 |
| 03:56 ET | 4738 | 4.48 |
| 03:57 ET | 2137 | 4.48 |
| 03:59 ET | 14841 | 4.52 |
Today
Apr 26, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA, from 9:03AM ET on Friday Apr 26, 2024 by Dow Jones
9:03AM ET on Friday Apr 26, 2024 by Dow Jones
Apr 24, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA, from 3:40PM ET on Wednesday Apr 24, 2024 by Dow Jones
3:40PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 20, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA, from 12:00PM ET on Saturday Apr 20, 2024 by Dow Jones
12:00PM ET on Saturday Apr 20, 2024 by Dow Jones
Apr 16, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA, from 3:20PM ET on Tuesday Apr 16, 2024 by Dow Jones
3:20PM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zevra Therapeutics Inc | 196.3M | -3.5x | --- |
Elite Pharmaceuticals Inc | 134.9M | 8.7x | --- |
Dbv Technologies SA | 122.7M | -1.8x | --- |
Eton Pharmaceuticals Inc | 88.6M | -88.7x | --- |
Scilex Holding Co | 146.3M | -0.7x | --- |
Cipla Ltd | 13.7B | 0.0x | --- |
Company Information
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Contact Information
- Headquarters
- 1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION, FL, United States 34747
- Phone
- 321-939-3416
- Fax
- 319-665-2577
Executives
- Independent Chairman of the Board
- Tamara Seymour
- President, Chief Executive Officer, Director
- Neil Mcfarlane
- Chief Financial Officer, Treasurer, Secretary
- R. LaDuane Clifton
- Executive Vice President - Research and Development
- Sven Guenther
- Senior Vice President - Medical Affairs and Advocacy
- Daniel Gallo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $196.3M |
|---|---|
Revenue (TTM) | $27.5M |
Shares Outstanding | 43.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.88 |
EPS | $-1.29 |
Book Value | $1.49 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | 7.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -180.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
